WILMINGTON, DEL. (CN) - MedImmune's human papillomavirus virus vaccine, Cervarix, will generate $2 billion a year and MedImmune plans to stiff the nonprofit Boyce Thompson Institute for Plant Research, which supplied it with the "high five cell line" technology that made the vaccine possible, Boyce Thompson claims in New Castle Superior Court.
MedImmune, a subsidiary of AstraZeneca, stole and converted trade secrets, in breach of contract, and plans to sell the blockbuster drug with a partner, GlaxoSmithKline, says Boyce Thompson, which seeks punitive damages. See complaint.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.
Additional Reads
-
-
EU regulator advises AstraZeneca's Covid drug be cleared March 24, 2022